Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Unknown 2Completed 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thyroid Neoplasms 1Solid Tumor Cancer 1Esophageal Squamous Cell Carcinoma 1

Interventions

toripalimab 6Cisplatin 5130-nm albumin-bound paclitaxel 5Drug Therapy 4tislelizumab 3sintilimab 3camrelizumab 3Injections 3Immune Checkpoint Inhibitors 3Fluorouracil 3Carboplatin 3nedaplatin 2anlotinib 2Radiotherapy 2Paclitaxel 2Neoadjuvant Therapy 2Irinotecan 2Esophagectomy 2potassium oxonate 1pembrolizumab 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1Watchful Waiting 1Taxes 1TP protocol 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Esophageal Squamous Cell Carcinoma × TP protocol × Clear all
NCT06588335 2024-09-19

BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Henan Provincial People's Hospital

Phase 2 Not yet recruiting
20 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡